TD Cowen raised the firm’s price target on Neurocrine to $125 from $120 and keeps an Outperform rating on the shares. The firm noted its Q2 beat and raised guidance as well as upcoming catalysts in Q4 with late-stage readouts.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine price target raised to $148 from $140 at Baird
- Neurocrine raises 2023 net product sales view to $1.77B-$1.82B
- Neurocrine reports Q2 non-GAAP EPS $1.25, consensus 78c
- Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
- NBIX Earnings Report this Week: Is It a Buy, Ahead of Earnings?